295 related articles for article (PubMed ID: 25379018)
21. Stage III & IV colon and rectal cancers share a similar genetic profile: a review of the Oregon Colorectal Cancer Registry.
Gawlick U; Lu KC; Douthit MA; Diggs BS; Schuff KG; Herzig DO; Tsikitis VL
Am J Surg; 2013 May; 205(5):608-12; discussion 612. PubMed ID: 23592171
[TBL] [Abstract][Full Text] [Related]
22. KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX.
Lee DW; Kim KJ; Han SW; Lee HJ; Rhee YY; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Ann Surg Oncol; 2015 Jan; 22(1):187-94. PubMed ID: 24889488
[TBL] [Abstract][Full Text] [Related]
23. Polymorphisms in insulin-related genes predispose to specific KRAS2 and TP53 mutations in colon cancer.
Samowitz WS; Wolff RK; Ma KN; Andersen K; Caan B; Slattery ML
Mutat Res; 2006 Mar; 595(1-2):117-24. PubMed ID: 16448675
[TBL] [Abstract][Full Text] [Related]
24. HSP27 expression in primary colorectal cancers is dependent on mutation of KRAS and PI3K/AKT activation status and is independent of TP53.
Ghosh A; Lai C; McDonald S; Suraweera N; Sengupta N; Propper D; Dorudi S; Silver A
Exp Mol Pathol; 2013 Feb; 94(1):103-8. PubMed ID: 22982087
[TBL] [Abstract][Full Text] [Related]
25. Prognostic value of BRAF and KRAS mutation status in stage II and III microsatellite instable colon cancers.
de Cuba EM; Snaebjornsson P; Heideman DA; van Grieken NC; Bosch LJ; Fijneman RJ; Belt E; Bril H; Stockmann HB; Hooijberg E; Punt CJ; Koopman M; Nagtegaal ID; Coupé VH; Carvalho B; Meijer GA
Int J Cancer; 2016 Mar; 138(5):1139-45. PubMed ID: 26376292
[TBL] [Abstract][Full Text] [Related]
26. Inter- and intra-tumor profiling of multi-regional colon cancer and metastasis.
Kogita A; Yoshioka Y; Sakai K; Togashi Y; Sogabe S; Nakai T; Okuno K; Nishio K
Biochem Biophys Res Commun; 2015 Feb; 458(1):52-6. PubMed ID: 25623536
[TBL] [Abstract][Full Text] [Related]
27. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
[TBL] [Abstract][Full Text] [Related]
28. Identification of a poor-prognosis BRAF-mutant-like population of patients with colon cancer.
Popovici V; Budinska E; Tejpar S; Weinrich S; Estrella H; Hodgson G; Van Cutsem E; Xie T; Bosman FT; Roth AD; Delorenzi M
J Clin Oncol; 2012 Apr; 30(12):1288-95. PubMed ID: 22393095
[TBL] [Abstract][Full Text] [Related]
29. EGFR activating aberration occurs independently of other genetic aberrations or telomerase activation in adenocarcinoma of the lung.
Arifin M; Hiyama K; Tanimoto K; Wiyono WH; Hiyama E; Nishiyama M
Oncol Rep; 2007 Jun; 17(6):1405-11. PubMed ID: 17487398
[TBL] [Abstract][Full Text] [Related]
30. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
31. KRAS, BRAF, and TP53 deep sequencing for colorectal carcinoma patient diagnostics.
Rechsteiner M; von Teichman A; Rüschoff JH; Fankhauser N; Pestalozzi B; Schraml P; Weber A; Wild P; Zimmermann D; Moch H
J Mol Diagn; 2013 May; 15(3):299-311. PubMed ID: 23531339
[TBL] [Abstract][Full Text] [Related]
32. KRAS mutations are associated with specific morphologic features in colon cancer.
Gunal A; Hui P; Kilic S; Xu R; Jain D; Mitchell K; Robert M; Kenney B
J Clin Gastroenterol; 2013 Jul; 47(6):509-14. PubMed ID: 23090042
[TBL] [Abstract][Full Text] [Related]
33. The impact of TP53 and RAS mutations on cerebellar glioblastomas.
Milinkovic VP; Skender Gazibara MK; Manojlovic Gacic EM; Gazibara TM; Tanic NT
Exp Mol Pathol; 2014 Oct; 97(2):202-7. PubMed ID: 25036404
[TBL] [Abstract][Full Text] [Related]
34. Prognostic relevance of occult metastases detected by cytokeratin 20 and mucin 2 mRNA levels in sentinel lymph nodes from colon cancer patients.
Nordgård O; Oltedal S; Aasprong OG; Søreide JA; Søreide K; Tjensvoll K; Gilje B; Heikkilä R; Guriby M; Lothe RA; Smaaland R; Kørner H
Ann Surg Oncol; 2012 Nov; 19(12):3719-26. PubMed ID: 22752373
[TBL] [Abstract][Full Text] [Related]
35. TRAIL receptor upregulation and the implication of KRAS/BRAF mutations in human colon cancer tumors.
Oikonomou E; Kosmidou V; Katseli A; Kothonidis K; Mourtzoukou D; Kontogeorgos G; Andera L; Zografos G; Pintzas A
Int J Cancer; 2009 Nov; 125(9):2127-35. PubMed ID: 19637313
[TBL] [Abstract][Full Text] [Related]
36. Chromosomal instability in mouse metastatic pancreatic cancer--it's Kras and Tp53 after all.
Siveke JT; Schmid RM
Cancer Cell; 2005 May; 7(5):405-7. PubMed ID: 15894260
[TBL] [Abstract][Full Text] [Related]
37. Unique Genetic and Survival Characteristics of Invasive Mucinous Adenocarcinoma of the Lung.
Shim HS; Kenudson M; Zheng Z; Liebers M; Cha YJ; Hoang Ho Q; Onozato M; Phi Le L; Heist RS; Iafrate AJ
J Thorac Oncol; 2015 Aug; 10(8):1156-62. PubMed ID: 26200269
[TBL] [Abstract][Full Text] [Related]
38. Correlation of telomere length shortening with TP53 somatic mutations, polymorphisms and allelic loss in breast tumors and esophageal cancer.
Hao XD; Yang Y; Song X; Zhao XK; Wang LD; He JD; Kong QP; Tang NL; Zhang YP
Oncol Rep; 2013 Jan; 29(1):226-36. PubMed ID: 23124483
[TBL] [Abstract][Full Text] [Related]
39. TP53-dependent chromosome instability is associated with transient reductions in telomere length in immortal telomerase-positive cell lines.
Schwartz JL; Jordan R; Liber H; Murnane JP; Evans HH
Genes Chromosomes Cancer; 2001 Mar; 30(3):236-44. PubMed ID: 11170280
[TBL] [Abstract][Full Text] [Related]
40. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
